• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nascent Biotech Inc (OP: NBIO )

    0.0899 +0.0071 (+8.57%)
    Streaming Delayed Price Updated: 9:40 AM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 23,698
    Open 0.0824
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0828
    Today's Range 0.0731 - 0.0899
    52wk Range 0.0413 - 0.2800
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
    Via ACCESSWIRE
    Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
    Via ACCESSWIRE

    Performance

    YTD
    -44.33%
    -44.33%
    1 Month
    -7.89%
    -7.89%
    3 Month
    -44.95%
    -44.95%
    6 Month
    -50.03%
    -50.03%
    1 Year
    +83.47%
    +83.47%

    More News

    Read More
    Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
    Via ACCESSWIRE
    Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
    Via ACCESSWIRE
    Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
    Via ACCESSWIRE
    Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
    Via ACCESSWIRE
    Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
    Via ACCESSWIRE
    Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
    Via ACCESSWIRE
    Nascent Biotech Regains Worldwide Rights for Pritumumab
    Via ACCESSWIRE
    Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
    Via ACCESSWIRE
    Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
    Via ACCESSWIRE
    Nascent Announces the Completion of Its Phase1 Clinical Trials
    Via ACCESSWIRE
    Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
    Via ACCESSWIRE
    Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
    Via ACCESSWIRE
    Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
    Via ACCESSWIRE
    Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
    Via ACCESSWIRE
    Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
    Via ACCESSWIRE
    Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
    Via ACCESSWIRE
    Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
    Via ACCESSWIRE
    Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
    From Nascent Biotech Inc.
    Via AccessWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
    From Nascent Biotech Inc.
    Via AccessWire
    Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
    From Nascent Biotech Inc.
    Via AccessWire
    Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
    From Nascent Biotech Inc.
    Via AccessWire
    The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial
    From Nascent Biotech Inc.
    Via AccessWire
    Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
    From Nascent Biotech Inc.
    Via AccessWire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.